Key result
Peripheral caspase-1 mRNA levels were significantly higher in multiple sclerosis patients than healthy controls (p<0.001) and increased twofold to threefold in the week preceding an acute attack.
Why the study?
Do peripheral levels of caspase-1 mRNA correlate with disease activity in patients with relapsing-remitting multiple sclerosis?
Observational (n=7)
Do peripheral levels of caspase-1 mRNA correlate with disease activity in patients with relapsing-remitting multiple sclerosis?
p-value: p=<0.001
Peripheral caspase-1 mRNA levels correlate with clinical and MRI disease activity in relapsing-remitting multiple sclerosis, suggesting its potential as an immunological marker.
Caspase-1 mRNA may support biomarker development in RRMS; hypothesis-generating and requires prospective validation before clinical use.
The cysteine protease caspase-1 plays a crucial part in the inflammatory process due to its ability to proteolitically activate proinflammatory cytokine precursors, such as interleukin (IL)-1beta and IL-18. Multiple sclerosis is a chronic inflammatory demyelinating disease of the CNS in which the pathogenic process is mainly orchestrated by proinflammatory cytokines. The role of caspase-1 in multiple sclerosis was evaluated by measuring its mRNA levels in peripheral blood mononuclear cells (PBMCs) from seven patients with relapsing-remitting multiple sclerosis every 15 days over a 1 year period. The recorded levels were compared with clinical and MRI evidence of disease activity. Brain MRI was performed monthly in each patient. Caspase-1 mRNA levels were significantly increased in PBMCs from patients with multiple sclerosis compared with healthy controls (p<0.001). In patients with multiple sclerosis, a twofold to threefold increase of caspase-1 mRNA mean level was found in the week preceding an acute attack (p<0. 05). The magnitude of caspase-1 mRNA increase correlated with the number of new (p=0.01) but not persisting gadolinium enhancing brain MRI lesions. In conclusion, caspase-1 might be involved in the immune mediated process underlying CNS inflammation and might represent a suitable peripheral immunological marker of disease activity in multiple sclerosis.
No takes yet. Share an insight, caveat, or question.
Furlan et al. (1999) conducted an observational in Relapsing-remitting multiple sclerosis (n=7). Caspase-1 mRNA level measurement vs. Healthy controls was evaluated on Caspase-1 mRNA levels in peripheral blood mononuclear cells (p=<0.001). Peripheral caspase-1 mRNA levels were significantly higher in multiple sclerosis patients than healthy controls (p<0.001) and increased twofold to threefold in the week preceding an acute attack.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: